当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2013年
32期
115-117
,共3页
结外NK/T细胞淋巴瘤%淋巴瘤%分期%预后%治疗
結外NK/T細胞淋巴瘤%淋巴瘤%分期%預後%治療
결외NK/T세포림파류%림파류%분기%예후%치료
Nasal type extranodal NK/T cell lymphoma%Lymphoma%Staging%Prognosis%Treatment
目的:探讨结外NK/T细胞鼻型淋巴瘤临床特征、诊疗方案和预后。方法收集5例结外NK/T细胞淋巴瘤鼻型患者的临床资料,分析其临床表现、辅助检查、治疗情况及追踪结局,结合相关文献进行总结。结果5例患者以鼻塞、鼻出血、咽痛、腭部溃疡为主要临床表现。最终靠病理活检及免疫组化明确诊断。根据Ann Arbor分期:ⅡE期1例,ⅢE期2例,ⅣE期2例。有B症状4例。5例患者预后评估1例中高危,4例高危。2例接受含有左旋门冬酰胺酶的方案化疗及联合放疗的患者1例完全缓解,1例部分缓解,定期门诊随访;3例放弃治疗的患者均死亡,自然病程小于6个月。结论结外NK/T细胞淋巴瘤鼻型属T细胞侵袭性淋巴瘤,其发病与EB病毒关系密切,恶性程度高,目前治疗方法主要有放疗、化疗及骨髓移植,靶向治疗可作为今后的研究方向。
目的:探討結外NK/T細胞鼻型淋巴瘤臨床特徵、診療方案和預後。方法收集5例結外NK/T細胞淋巴瘤鼻型患者的臨床資料,分析其臨床錶現、輔助檢查、治療情況及追蹤結跼,結閤相關文獻進行總結。結果5例患者以鼻塞、鼻齣血、嚥痛、腭部潰瘍為主要臨床錶現。最終靠病理活檢及免疫組化明確診斷。根據Ann Arbor分期:ⅡE期1例,ⅢE期2例,ⅣE期2例。有B癥狀4例。5例患者預後評估1例中高危,4例高危。2例接受含有左鏇門鼕酰胺酶的方案化療及聯閤放療的患者1例完全緩解,1例部分緩解,定期門診隨訪;3例放棄治療的患者均死亡,自然病程小于6箇月。結論結外NK/T細胞淋巴瘤鼻型屬T細胞侵襲性淋巴瘤,其髮病與EB病毒關繫密切,噁性程度高,目前治療方法主要有放療、化療及骨髓移植,靶嚮治療可作為今後的研究方嚮。
목적:탐토결외NK/T세포비형림파류림상특정、진료방안화예후。방법수집5례결외NK/T세포림파류비형환자적림상자료,분석기림상표현、보조검사、치료정황급추종결국,결합상관문헌진행총결。결과5례환자이비새、비출혈、인통、악부궤양위주요림상표현。최종고병리활검급면역조화명학진단。근거Ann Arbor분기:ⅡE기1례,ⅢE기2례,ⅣE기2례。유B증상4례。5례환자예후평고1례중고위,4례고위。2례접수함유좌선문동선알매적방안화료급연합방료적환자1례완전완해,1례부분완해,정기문진수방;3례방기치료적환자균사망,자연병정소우6개월。결론결외NK/T세포림파류비형속T세포침습성림파류,기발병여EB병독관계밀절,악성정도고,목전치료방법주요유방료、화료급골수이식,파향치료가작위금후적연구방향。
Objective To discuss the clinical characteristic of the nasal type extranodal NK/T cell lymphoma(ENK-TCL) as well as the therapeutic regimen and prognosis. Methods The clinical information of the 5 patients confirmed ENK-TCL were collected, the clinical manifestation, auxiliary examinations, treatments were analyzed and tracked the end. Results The main clinical features of the 5 patients were rhinobyon, epistaxis, sore throat and jaws ulcer. They were fanally diagnosed by pathologic biopsy and immunohistochemistry. Ann Arbor stage ⅡE 1 case,ⅢE 2 cases andⅣE 2 cases. B symptoms 4 cases. One case was at high risk of prognostic evaluation,4 cases were high risk.2 patients received chemotherapy contains L-asparaginasum and radiotherapy, of whom 1 case received complete remission(CR) and 1 case partial remission(PR), and outpatient service follow-up regularly;3 cases abandoning theropy died within 6 months. Conclusion ENK-TCL is belong to T cell aggressive lymphoma and related to Epstein-Barr(EB) virus. Malignant degree is high. The main treatments are radiotherapy, chemotherapy and bone marrow transplantation, and the targeted therapy could be the future research area.